



Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial[†]

Arie Pieter Kappetein^{a,*}, Stuart J. Head^a, Marie-Claude Morice^b, Adrian P. Banning^c, Patrick W. Serruys^d, Friedrich-Wilhelm Mohr^e, Keith D. Dawkins^f and Michael J. Mack^g on behalf of the SYNTAX Investigators

^a Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, Netherlands

^b Department of Cardiology, Institut Hospitalier Jacques Cartier, Massy, France

^c Department of Cardiovascular Medicine, John Radcliffe Hospital, Oxford, UK

^d Department of Cardiology, Erasmus University Medical Center, Rotterdam, Netherlands

^e Department of Cardiac Surgery, Herzzentrum, Leipzig, Germany

^f Boston Scientific Corporation, Natick, MA, USA

^g Department of Cardiovascular Medicine, The Heart Hospital, Baylor Healthcare System, Plano, TX, USA

* Corresponding author. Department of Cardiothoracic Surgery, Erasmus University Medical Center, P.O. Box 2040, 3000 CA Rotterdam, Netherlands. Tel: +31-10-7032150; fax: +31-10-7033993; e-mail: a.kappetein@erasmusmc.nl (A.P. Kappetein).

Received 10 October 2012; received in revised form 21 November 2012; accepted 7 December 2012

Abstract

OBJECTIVES: This prespecified subgroup analysis examined the effect of diabetes on left main coronary disease (LM) and/or three-vessel disease (3VD) in patients treated with percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) in the SYNTAX trial.

METHODS: Patients ($n = 1800$) with LM and/or 3VD were randomized to receive either PCI with TAXUS Express paclitaxel-eluting stents or CABG. Five-year outcomes in subgroups with ($n = 452$) or without ($n = 1348$) diabetes were examined: major adverse cardiac or cerebrovascular events (MACCE), the composite safety end-point of all-cause death/stroke/myocardial infarction (MI) and individual MACCE components death, stroke, MI and repeat revascularization. Event rates were estimated with Kaplan–Meier analyses.

RESULTS: In diabetic patients, 5-year rates were significantly higher for PCI vs CABG for MACCE (PCI: 46.5% vs CABG: 29.0%; $P < 0.001$) and repeat revascularization (PCI: 35.3% vs CABG: 14.6%; $P < 0.001$). There was no difference in the composite of all-cause death/stroke/MI (PCI: 23.9% vs CABG: 19.1%; $P = 0.26$) or individual components all-cause death (PCI: 19.5% vs CABG: 12.9%; $P = 0.065$), stroke (PCI: 3.0% vs CABG: 4.7%; $P = 0.34$) or MI (PCI: 9.0% vs CABG: 5.4%; $P = 0.20$). In non-diabetic patients, rates with PCI were also higher for MACCE (PCI: 34.1% vs CABG: 26.3%; $P = 0.002$) and repeat revascularization (PCI: 22.8% vs CABG: 13.4%; $P < 0.001$), but not for the composite end-point of all-cause death/stroke/MI (PCI: 19.8% vs CABG: 15.9%; $P = 0.069$). There were no differences in all-cause death (PCI: 12.0% vs CABG: 10.9%; $P = 0.48$) or stroke (PCI: 2.2% vs CABG: 3.5%; $P = 0.15$), but rates of MI (PCI: 9.9% vs CABG: 3.4%; $P < 0.001$) were significantly increased in the PCI arm in non-diabetic patients.

CONCLUSIONS: In both diabetic and non-diabetic patients, PCI resulted in higher rates of MACCE and repeat revascularization at 5 years. Although PCI is a potential treatment option in patients with less-complex lesions, CABG should be the revascularization option of choice for patients with more-complex anatomic disease, especially with concurrent diabetes.

Keywords: Percutaneous coronary intervention • Coronary artery bypass grafting • Diabetes • SYNTAX

INTRODUCTION

The global prevalence of diabetes mellitus has continuously increased over the last decades, currently affecting more than 347 million people [1, 2]. Diabetes is a common co-morbidity in patients with coronary artery disease who are evaluated for revascularization, and is shown to be a predictor of adverse events during follow-up after coronary artery bypass grafting

(CABG) and percutaneous coronary intervention (PCI) [3–5]. However, long-term data from randomized trials are limited, particularly for the comparison between CABG and PCI with drug-eluting stents.

The Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial compared PCI with paclitaxel-eluting stents (PES) and CABG for patients with *de novo* three-vessel and/or left main disease [6, 7]. Prespecified subgroup analyses of diabetic vs non-diabetic patients have been reported at 1- and 3-year follow-up [8, 9]. This study examined the impact of diabetes on 5-year outcomes after PCI and CABG.

[†]Presented at the 26th Annual Meeting of the European Association for Cardio-Thoracic Surgery, Barcelona, Spain, 27–31 October 2012.

METHODS

Study design

The design and methods of the SYNTAX trial have been reported previously [10]. It was a prospective multinational randomized (1:1) trial in which 1800 patients with *de novo* three-vessel and/or left main coronary artery disease were randomly assigned to undergo PCI with TAXUS Express paclitaxel-eluting stents (Boston Scientific, Natick, MA, USA) or CABG. Based on the clinical judgment and consensus of a multidisciplinary Heart Team consisting of a cardiovascular surgeon and an interventional cardiologist [11], patients with anticipated clinical revascularization equipose through PCI and CABG were randomized (CABG: $n = 897$, PCI: $n = 903$). Those with expected unfavourable outcomes for PCI or CABG were included in the CABG-ineligible PCI registry ($n = 198$) or PCI-ineligible CABG registry ($n = 1077$), respectively [12]. Five-year clinical follow-up was completed by a clinic visit or telephone call in 86.5% of CABG patients and 94.5% of PCI patients. Follow-up was complete (clinical follow-up or death) in 88.0 and 95.2%, respectively.

Randomization was stratified according to the status of diabetes and left main disease. The subgroup analysis according to diabetes status was prespecified in the trial protocol, although no formal statistical hypothesis was defined *a priori*.

The institutional review board of each of the 85 participating sites approved the protocol. All patients provided written informed consent before enrolment. The trial is registered on the National Institute of Health website with identifier NCT00114972.

Definitions

Medically treated diabetes was defined as treatment with oral hypoglycaemic agents or insulin at the time of enrolment. The composite end-point of major adverse cardiac or cerebrovascular events (MACCE) included all-cause death, cerebrovascular accident (CVA), myocardial infarction (MI) or repeat revascularization (subsequent PCI or CABG). Cerebrovascular events, or stroke, were defined as focal neurological deficits of central origin lasting >72 h, resulting in permanent brain damage or body impairment. MI was defined in relation to intervention status as follows: (i) after allocation but before treatment: Q-wave [new pathological Q-waves in ≥ 2 leads lasting ≥ 0.04 s with creatine kinase-MB (CK-MB) levels elevated above normal] and non-Q-wave MI [elevation of CK levels $>2\times$ the upper limit of normal (ULN) with positive CK-MB or elevation of CK levels to $>2\times$ ULN without new Q-waves if no baseline CK-MB was available]; (ii) <7 days after intervention: new Q-waves and either peak CK-MB/total CK $>10\%$ or plasma level of CK-MB $5\times$ ULN and (iii) ≥ 7 days after intervention: new Q-waves or peak CK-MB/total CK $>10\%$ or plasma level of CK-MB $5\times$ ULN. The CK/CK-MB enzyme levels were obtained and measured by a core laboratory for all randomized patients. An independent Clinical Event Committee adjudicated the events.

Statistical analysis

All analyses were according to the intention-to-treat principle and performed using SAS software version 8.0 or higher (SAS

Institute, Cary, NC, USA). Data are summarized using descriptive statistics, presented as proportions (%), count/sample size) or mean \pm standard deviation. Continuous variables were compared using the Student's *t*-test; differences in discrete variables were assessed with the χ^2 test or Fisher's exact test, where appropriate. Time-to-event Kaplan–Meier estimates with log-rank testing were used to compare PCI and CABG in diabetic and non-diabetic patients, and to compare diabetics vs non-diabetics in PCI and CABG groups. *P*-values for interaction were generated by logistic regression χ^2 test. *Post hoc* subgroup analyses according to SYNTAX Score tertiles (low: 0–22, intermediate: 23–32, high: ≥ 33) were performed using time-to-event Kaplan–Meier estimates [13]. Univariate analysis, including a combination of preoperative and intraoperative variables, was used to identify potential predictors of 5-year outcomes. Subsequently, multivariate predictors of MACCE, the composite safety end-point of all-cause death/stroke/MI, and repeat revascularization after PCI and CABG were identified using stepwise selection with a significance level of <0.10 for entry and exit in a logistic regression model. A *P*-value <0.05 was considered to be statistically significant.

RESULTS

Baseline characteristics

In the SYNTAX trial, 1800 patients were randomly assigned to PCI ($n = 903$) and CABG ($n = 897$), producing two well-matched treatment groups [6]. Compared with non-diabetic patients ($n = 1348$), those with diabetes ($n = 452$) had a significantly higher risk profile, which was reflected in a higher EuroSCORE of 4.0 ± 2.7 vs 3.7 ± 2.6 , respectively ($P = 0.027$) (Table 1). Diabetics also had more coronary lesions (4.6 ± 1.8 vs 4.3 ± 1.8 , $P = 0.003$) and a trend towards more diffuse disease or small vessels (13 vs 10%, $P = 0.061$), although the mean SYNTAX Score was comparable with non-diabetics (29.0 ± 11.2 vs 28.6 ± 11.5 , $P = 0.52$).

Diabetes status subgroups

Table 2 lists the clinical outcomes according to diabetes status and treatment arm. The rate of MACCE was significantly different between CABG and PCI among both non-diabetic and diabetic patients (Fig. 1). There were no differences in the composite safety end-point of all-cause death/stroke/MI in non-diabetic or diabetic patients. Rates of all-cause death were similar among non-diabetic CABG and PCI patients [HR = 1.12 (95% CI 0.81–1.55), $P = 0.48$], and diabetic patients [HR = 1.57 (95% CI 0.97–2.55), $P = 0.065$]. Cardiac death was significantly more frequent in patients treated with PCI than those who underwent CABG, in non-diabetics [HR = 1.62 (95% CI 1.03–2.55); $P = 0.035$] and diabetics [HR = 2.01 (95% CI 1.04–3.88); $P = 0.034$]. Increased repeat revascularization after PCI when compared with CABG was present in non-diabetic [HR = 1.82 (95% CI 1.39–2.38); $P < 0.001$] and diabetic [HR = 2.75 (95% CI 1.78–4.24); $P < 0.001$] patients. There was a significantly higher rate of MI after PCI than after CABG in non-diabetic patients [HR = 2.90 (95% CI 1.79–4.70); $P < 0.001$], but this was not significant in diabetic patients [HR = 1.62 (95% CI 0.77–3.41); $P = 0.20$]. There were no differences in stroke or graft occlusion/stent thrombosis between groups.

Table 1: Baseline characteristics

	Non-diabetic (n = 1348)	Diabetic (n = 452)	P-value
Age (years)	65.0 ± 9.9 (1348)	65.4 ± 9.2	0.049
Male gender	79.9 (1077/1348)	71.0 (321/452)	<0.001
Comorbid risk factors			
Body mass index (kg/m ²)	27.5 ± 4.4	29.5 ± 5.2	<0.001
Metabolic syndrome ^a	37% (398/1064)	70% (258/369)	<0.001
Waist >40 in. for male, >35 in. for female	42% (502/1194)	61% (238/393)	<0.001
Triglycerides ≥150 mg/dl ^b	33% (409/1230)	42% (170/408)	0.002
HDL <40 mg/dl male, <50 mg/dl female ^b	45% (544/1199)	61% (238/389)	<0.001
Blood pressure ≥130/85 mmHg	65% (80/1348)	70% (316/452)	0.071
Fasting glucose ≥110 mg/dl	28% (260/934)	82% (286/348)	<0.001
Haemoglobin A1c ≥7.0% ^b	3% (31/1179)	57% (215/378)	<0.001
Hyperlipidaemia	77% (1029/1341)	82% (362/444)	0.035
Medically treated diabetes	0% (0/1348)	100% (452/452)	<0.001
Insulin-requiring diabetes	0% (0/1348)	40% (182/452)	<0.001
Cardiovascular history			
Current smoker	22% (292/1343)	16% (71/450)	0.006
Prior myocardial infarction	33% (442/1333)	32% (143/447)	0.65
Congestive heart failure	4% (50/1334)	7% (33/444)	0.001
Carotid artery disease	7% (99/1348)	11% (49/452)	0.019
Prior cerebrovascular accident	4% (51/1341)	6% (27/448)	0.046
Prior transient ischaemic attack	4% (58/1341)	6% (26/448)	0.20
Peripheral vascular disease	8% (111/1348)	15% (66/452)	<0.001
Creatinine >200 μmol/l	1% (13/1348)	3% (13/452)	0.003
Unstable angina	28% (378/1348)	30% (134/452)	0.51
LVEF <30% ^c	2% (21/1348)	3% (13/452)	0.075
Parsonnet score	7.5 ± 6.8	11.3 ± 6.4	<0.001
Additive EuroSCORE ^d	3.7 ± 2.6	4.0 ± 2.7	0.027
Lesion complexity			
Diffuse disease or small vessels ^b	10% (136/1338)	13% (60/449)	0.061
SYNTAX score ^b	28.6 ± 11.5	29.0 ± 11.2	0.52
Lesion characteristics			
Number of lesions ^b	4.3 ± 1.8	4.6 ± 1.8	0.003
Left main, any ^b	36% (480/1338)	29% (130/449)	0.007
Left main only	4% (52/1338)	2% (10/449)	0.096
Left main + 1-vessel	6% (75/1338)	4% (18/449)	0.19
Left main + 2-vessel	12% (160/1338)	11% (50/449)	0.64
Left main + 3-vessel	14% (193/1338)	12% (52/449)	0.13
Three-vessel disease only ^b	64% (858/1338)	71% (319/449)	0.007

Values are shown as mean ± SD (n) or % (n/N). Reprinted from Ref. [8].

HDL: high-density lipoprotein; LVEF: left ventricular ejection fraction.

^aMetabolic syndrome was defined as at least three of the following: (i) waist circumference >40 in. for male or >35 in. for female; (ii) triglycerides ≥150 mg/dl; (iii) high-density lipoprotein <40 mg/dl for male or <50 mg/dl for female; (iv) blood pressure ≥130/85 mmHg and (v) fasting glucose ≥110 mg/dl [25].

^bCore laboratory reported.

^cOr indicated by clinical site as 'poor' if exact value was not available.

^dAdditive EuroSCORE calculated from site-reported baseline data.

Although patients with diabetes who underwent CABG had numerically higher rates of clinical adverse events than non-diabetic CABG patients, there were no statistically significant differences at 5-year follow-up. However, diabetic patients who underwent PCI had significantly higher rates of MACCE ($P < 0.001$), death ($P = 0.003$) and repeat revascularization ($P < 0.001$) than non-diabetic patients. There were no significant interactions between diabetes status and treatment.

Diabetes control subgroups

Subgroup analyses according to diabetes treatment (oral hypoglycaemic agents or insulin) (Table 3) showed that the MACCE

rate was significantly increased after PCI in the group on oral hypoglycaemic agents (PCI: 40.4% vs CABG: 26.4%; $P = 0.022$) and insulin (PCI: 56.2% vs CABG: 32.6%; $P = 0.002$). Rates of repeat revascularization were also higher in both the insulin-dependent and the oral hypoglycaemic groups (PCI: 29.9% vs CABG: 12.0%; $P < 0.001$ and PCI: 44.3% vs CABG: 18.1%; $P = 0.001$, respectively). However, the composite safety end-point of all-cause death/stroke/MI was comparable between PCI and CABG in the group on oral hypoglycaemic agents (PCI: 18.8% vs CABG: 17.7%; $P = 0.92$), although there was a significantly higher rate of cardiac death (PCI: 18.8% vs CABG: 7.1%; $P = 0.023$) in patients who underwent PCI. There were no differences in stroke or MI in the groups of patients on oral hypoglycaemic agents or insulin.

Table 2: Five-year clinical outcomes according to diabetes status

Clinical outcome	Non-diabetic (n = 1348)			Diabetic (n = 452)			Non-diabetic vs diabetic		Interaction P-value ^a
	CABG (n = 676)	PCI (n = 672)	P-value	CABG (n = 221)	PCI (n = 231)	P-value	P-value (CABG)	P-value (PCI)	
MACCE ^b	26.3% (167)	34.1% (226)	0.002	29.0% (59)	46.5% (105)	<0.001	0.37	<0.001	0.17
All-cause death/stroke/myocardial infarction	15.9% (101)	19.8% (131)	0.069	19.1% (39)	23.9% (54)	0.26	0.25	0.18	0.76
All-cause death	10.9% (68)	12.0% (79)	0.48	12.9% (26)	19.5% (44)	0.065	0.34	0.003	0.43
Cardiac death	4.9% (30)	7.7% (50)	0.035	6.5% (13)	12.7% (28)	0.034	0.31	0.018	
Stroke	3.5% (22)	2.2% (14)	0.15	4.7% (9)	3.0% (6)	0.34	0.49	0.55	0.97
Myocardial infarction	3.4% (22)	9.9% (64)	<0.001	5.4% (11)	9.0% (19)	0.20	0.22	0.66	0.18
Repeat revascularization	13.4% (82)	22.8% (145)	<0.001	14.6% (28)	35.3% (75)	<0.001	0.60	<0.001	0.081
PCI	12.9% (78)	19.3% (123)	0.001	12.9% (24)	28.5% (60)	<0.001	0.95	0.004	
CABG	1.1% (7)	5.8% (36)	<0.001	1.9% (4)	8.7% (18)	0.004	0.35	0.12	
Graft occlusion/stent thrombosis	3.9% (24)	5.6% (36)	0.14	4.3% (8)	5.3% (11)	0.61	0.84	0.84	0.73

Data are Kaplan-Meier time-to-event estimates expressed as % (n); log-rank P-value.

CABG: coronary artery bypass grafting; MACCE: major adverse cardiac or cerebrovascular events; PCI: percutaneous coronary intervention.

^aBinary logistic regression interaction term for diabetes status by treatment arm.

^bMACCE consists of all-cause death, stroke, myocardial infarction, or repeat revascularization (CABG or PCI) in any vessel.

The rate of graft occlusion or stent thrombosis was not significantly different in the oral hypoglycaemic agents group (PCI: 3.2% vs CABG: 5.7%; $P = 0.35$) or the patients who were on insulin (PCI: 8.6% vs CABG: 2.5%; $P = 0.081$). However, the interaction term was statistically significant ($P = 0.046$), suggesting a different impact of diabetes treatment effect on outcomes after PCI and CABG. None of the interaction terms for the other outcomes was significant.

SYNTAX score subgroups

Subgroup analyses according to the complexity of coronary artery disease demonstrated that there was a consistent increase in adverse events after PCI with increasing SYNTAX Scores, while this was not the case for CABG patients (Fig. 2). Event rates of MACCE and the composite safety end-point therefore showed a stepwise increase in the difference between PCI and CABG with increasing SYNTAX Scores, irrespective of the diabetes status. Among non-diabetic patients, the rates of repeat revascularization showed a similar trend as for MACCE and the composite safety end-point. However, in diabetic patients even in the low SYNTAX Score tertile, there was a significantly higher event rate after PCI than after CABG (PCI: 39.4% vs CABG: 17.2%; $P = 0.006$).

Multivariate analysis

The final multivariate model did not identify medically treated diabetes as an independent predictor in the CABG cohort. However, for patients who underwent PCI, medically treated diabetes was an independent predictor of MACCE (OR = 1.71 [95% CI 1.22–2.39]; $P = 0.002$) and repeat revascularization (OR = 1.73 [95% CI 1.27–2.36]; $P < 0.001$), but not for the composite safety end-point of all-cause death/stroke/MI.

DISCUSSION

This study examined the impact of diabetes on clinical outcomes after PCI and CABG in the SYNTAX trial. The rates of MACCE were significantly higher after PCI as compared to CABG in both the diabetic and the non-diabetic patient subgroups, and this difference is mainly driven by an increase in repeat revascularization. However, the difference between PCI and CABG is larger for patients with diabetes than for those without. In contrast to the previous 1- and 3-year follow-up reports, patients who underwent PCI also had significantly higher rates of cardiac death at 5 years.

Randomized comparisons between PCI and CABG for the treatment of coronary artery disease in diabetic patients have mainly been limited by subgroup analyses of large trials. These trials found no significant difference in long-term survival between the two treatment strategies for diabetic patients but were underpowered and limited by being *post hoc* exploratory subgroup analyses. The only analysis that found a significant benefit of CABG over PCI from the BARI trial included 353 patients and reported 10-year survival rates of 57.9 and 45.5% ($P = 0.025$), respectively [14]. These data of 10 randomized trials (of which only four used bare-metal stents) were summarized in a meta-analysis of 7794 patients, demonstrating that CABG is superior over PCI in diabetic patients [3]. A pooled analysis of trials exclusively using stents showed no difference in outcomes between PCI and CABG, irrespective of diabetes status [15]. The debate between PCI and CABG remained ongoing, but the introduction of drug-eluting stents was promising since it showed a reduction in the rate of restenosis in diabetic patients [16, 17]. This drove new analyses of CABG vs PCI with drug-eluting stents. Although results were indeed better with drug-eluting stents, PCI failed to reach non-inferiority to CABG in the first randomized trial dedicated to patients with diabetes (CARDia) [18]. Recently, the results from the randomized FREEDOM trial ($n = 1900$) even showed that CABG was superior to drug-eluting stents for the composite primary end-point of death, stroke and MI ($P = 0.005$) [19].




Figure 1: Five-year outcomes of percutaneous coronary intervention vs coronary artery bypass grafting in diabetic and non-diabetic patients. Kaplan-Meier estimates of (A and D) major adverse cardiac or cerebrovascular events (MACCE), (B and E) the composite end-point of all-cause death/stroke/myocardial infarction and (C and F) repeat revascularization in diabetic patients (A–C) and non-diabetic patients (D–F). CABG: coronary artery bypass grafting (dotted lines); PCI: percutaneous coronary intervention (solid lines).

This substudy of the SYNTAX trial was also from a hypothesis-generating subgroup analysis and, although predefined, should be interpreted with caution. Nevertheless, the results are similar to that from the CARDia and FREEDOM trials [18, 19]. There was a significant difference between PCI and CABG in clinical outcomes, which was more pronounced in diabetic than non-diabetic patients. This suggests that diabetes may be more relevant in PCI patients than in CABG patients. Clinical outcomes in CABG patients were similar for diabetic and non-diabetic patients, while outcomes after PCI were significantly worse for diabetic when compared with non-diabetic patients. A reason

for this might be that a patent distal graft functions as protection for future more proximal lesions caused by progressing diffuse disease. After PCI, progression of diffuse disease in diabetic patients forms new lesions that may cause ischaemia and/or symptoms. This may also explain why diabetes was not an independent predictor of MACCE after CABG in the SYNTAX trial [20, 21].

Analyses according to diabetes control show that insulin-dependent diabetic patients are particularly at higher risk of adverse events during follow-up. Diabetic patients on insulin who underwent PCI had significantly higher rates of MACCE, the

Table 3: Five-year clinical outcomes according to diabetes treatment

Clinical outcome	Oral hypoglycaemic agents (n = 270)			Insulin (n = 452)			Oral vs insulin treatment		Interaction P-value ^a
	CABG (n = 128)	PCI (n = 142)	P-value	CABG (n = 93)	PCI (n = 89)	P-value	P-value (CABG)	P-value (PCI)	
MACCE ^b	26.4% (31)	40.4% (56)	0.022	32.6% (28)	56.2% (49)	0.002	0.37	0.023	0.34
All-cause death/stroke/myocardial infarction	17.7% (21)	18.8% (26)	0.92	21.0% (18)	32.1% (28)	0.091	0.65	0.018	0.25
All-cause death	12.0% (14)	16.6% (23)	0.32	14.0% (12)	24.1% (21)	0.082	0.70	0.15	0.53
Cardiac death	6.0% (7)	8.9% (12)	0.42	7.1% (6)	18.8% (16)	0.023	0.79	0.030	
Stroke	5.2% (6)	1.6% (2)	0.094	4.0% (3)	5.2% (4)	0.65	0.56	0.13	0.17
Myocardial infarction	5.1% (6)	7.5% (10)	0.49	5.7% (5)	11.6% (9)	0.23	0.83	0.34	0.76
Repeat revascularization	12.0% (13)	29.9% (40)	<0.001	18.1% (15)	44.3% (35)	0.001	0.19	0.063	>0.99
PCI	12.9% (78)	24.8% (33)	0.004	15.0% (12)	34.6% (27)	0.005	0.41	0.21	
CABG	1.1% (7)	7.0% (9)	0.020	3.3% (3)	11.6% (9)	0.064	0.19	0.23	
Graft occlusion/stent thrombosis	5.7% (6)	3.2% (4)	0.35	2.5% (2)	8.6% (7)	0.081	0.30	0.072	0.046

Data are Kaplan–Meier time-to-event estimates expressed as % (n); log-rank P-value.

CABG: coronary artery bypass grafting; MACCE: major adverse cardiac or cerebrovascular events; PCI: percutaneous coronary intervention.

^aBinary logistic regression interaction term for diabetes status by treatment arm.

^bMACCE consists of all-cause death, stroke, myocardial infarction or repeat revascularization (CABG or PCI) in any vessel.

composite safety end-point of all-cause death/stroke/MI, and cardiac death than patients on oral hypoglycaemic agents who underwent PCI. Apart from MACCE and repeat revascularization, there were no significant differences between PCI and CABG for patients on oral hypoglycaemic agents. In contrast, compared with insulin-dependent patients who underwent CABG, those who underwent PCI had significantly more cardiac deaths ($P = 0.023$). Therefore, the Heart Team may particularly advocate for CABG to treat insulin-dependent patients, while it should be carefully assessed whether PCI should be preferred over medical therapy for insulin-dependent patients unsuitable for CABG. The SYNTAX trial did not include a medical therapy treatment arm, but it will be interesting to see what the new developments in improved antiplatelet therapy (e.g. prasugrel, ticagrelor) will contribute to the debate regarding PCI vs medical therapy for diabetics with complex coronary disease.

The complexity of coronary artery disease is crucial when considering different revascularization options. In contrast to the results from the FREEDOM trial where there was no treatment-by-SYNTAX Score interaction [19], previous studies found that the SYNTAX Score was a predictor of adverse events after PCI but not after CABG. In the current study, differences in outcomes increased incrementally with lesion complexity, even more so in diabetics than non-diabetics. However, recent evidence suggests that a Logistic Clinical SYNTAX Score—consisting of the SYNTAX Score, age, creatinine clearance and left ventricular ejection fraction—is a better predictor of 1-year all-cause death than the SYNTAX Score itself [22]. The addition of diabetes resulted in little improvement of the model performance of the Logistic Clinical SYNTAX Score. Nevertheless, in our study, the presence of diabetes seems to reinforce the superiority of CABG over PCI and current SYNTAX Score thresholds may need to be adjusted for patients with diabetes.

According to the SYNTAX study, CABG should remain the gold standard for patients with complex coronary artery disease, especially those with diabetes. However, new stents may have the

potential of reducing rates of adverse events after PCI. In the SYNTAX trial, paclitaxel-eluting stents were exclusively used, a stent that is less frequently used in current practice due to the superiority of other sirolimus- and everolimus-eluting stents. It is still unclear which stent should be preferred for patients with diabetes, since improved outcomes with sirolimus- or everolimus-eluting stents over paclitaxel-eluting stents for diabetics has been debated [23, 24]. In the FREEDOM trial, both paclitaxel- and sirolimus-eluting stents were used, but the absolute difference in the primary end-point between stenting and CABG did not differ: $\Delta 6.5$ and $\Delta 6.7\%$, respectively [19].

Study limitations

Subgroup analyses have been criticized by methodologists and should be interpreted with caution. The diabetes subgroup was predefined and stratified randomization was performed to ensure equal distribution of diabetic patients over the PCI and CABG treatment arms. Nevertheless, the current analyses were not adequately powered and the results should be viewed as ‘hypothesis-generating’ only.

The SYNTAX trial enrolled patients with complex left main and/or three-vessel disease, and the results should therefore not be extrapolated to the overall cohort of patients with symptomatic coronary artery disease evaluated for coronary revascularization.

CONCLUSION

In both diabetic and non-diabetic patients, PCI resulted in higher rates of MACCE, cardiac death and repeat revascularization at 5 years. Although PCI is a potential treatment option in patients with less-complex lesions, CABG should be the revascularization




Figure 2: Five-year outcomes for diabetic patients and nondiabetic patients according to anatomic lesion complexity, as measured by the SYNTAX Score. Binary event rates of (A and D) major adverse cardiac or cerebrovascular events (MACCE), (B and E) the composite end-point of all-cause death/stroke/myocardial infarction and (C and F) repeat revascularization in diabetic (A-C) and non-diabetic patients (D-F). Rates are separated according to SYNTAX Score tertiles, indicating low (0-22), intermediate (23-32) and high (≥ 33) anatomic lesion complexity. CABG: coronary artery bypass grafting (*open bars*); PCI: percutaneous coronary intervention (*solid bars*).

option of choice for patients with more-complex anatomic disease, particularly with concurrent diabetes.

ACKNOWLEDGEMENTS

The authors thank Vicki Houle and Jian Huang (Boston Scientific) for help preparing the manuscript and statistical analysis. The SYNTAX trial was sponsored and funded by Boston Scientific Corporation, Natick, MA, USA.

FUNDING

A.P. Kappetein, M.C. Morice, A.P. Banning and P.W. Serruys have received institutional research grant support from Boston

Scientific. A.P. Banning is partially funded by the NIHR Biomedical Research Centre in Oxford, United Kingdom.

Conflict of interest: Keith D. Dawkins is a full-time employee of Boston Scientific Corporation.

REFERENCES

- [1] Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ *et al.* Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. *Lancet* 2011;378:31-40.
- [2] Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabetes Care* 2004;27:1047-53.

- [3] Hlatky MA, Boothroyd DB, Bravata DM, Boersma E, Booth J, Brooks MM *et al.* Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. *Lancet* 2009;373:1190–7.
- [4] Roffi M, Angiolillo DJ, Kappetein AP. Current concepts on coronary revascularization in diabetic patients. *Eur Heart J* 2011;32:2748–57.
- [5] Onuma Y, Wykrzykowska JJ, Garg S, Vranckx P, Serruys PW. ARTS I and II Investigators. 5-Year follow-up of coronary revascularization in diabetic patients with multivessel coronary artery disease: insights from ARTS (arterial revascularization therapy study)-II and ARTS-I trials. *JACC Cardiovasc Interv* 2011;4:317–23.
- [6] Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ *et al.* SYNTAX Investigators. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. *N Engl J Med* 2009;360:961–72.
- [7] Kappetein AP, Feldman TE, Mack MJ, Morice MC, Holmes DR, Stahle E *et al.* Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. *Eur Heart J* 2011;32:2125–34.
- [8] Banning AP, Westaby S, Morice M-C, Kappetein AP, Mohr FW, Berti S *et al.* Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents. *J Am Coll Cardiol* 2010;55:1067–75.
- [9] Mack MJ, Banning AP, Serruys PW, Morice MC, Taeymans Y, Van Nooten G *et al.* Bypass versus drug-eluting stents at three years in SYNTAX patients with diabetes mellitus or metabolic syndrome. *Ann Thorac Surg* 2011;92:2140–6.
- [10] Ong AT, Serruys PW, Mohr FW, Morice MC, Kappetein AP, Holmes DR Jr *et al.* The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: design, rationale, and run-in phase. *Am Heart J* 2006;151:1194–204.
- [11] Head SJ, Kaul S, Mack MJ, Serruys PW, Taggart DP, Holmes DR Jr *et al.* The rationale for heart team decision-making for patients with stable complex coronary artery disease. *Eur Heart J* 2012; 10.1093/eurheartj/eh059.
- [12] Head SJ, Holmes DR Jr, Mack MJ, Serruys PW, Mohr FW, Morice M *et al.* Risk profile and 3-year outcomes from the SYNTAX percutaneous coronary intervention and coronary artery bypass grafting nested registries. *JACC Cardiovasc Interv* 2012;5:618–25.
- [13] Sianos G, Morel MA, Kappetein AP, Morice MC, Colombo A, Dawkins K *et al.* The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. *EuroIntervention* 2005;1:219–27.
- [14] The BARI Investigators. The final 10-year follow-up results from the BARI randomized trial. *J Am Coll Cardiol* 2007;49:1600–6.
- [15] Daemen J, Boersma E, Flather M, Booth J, Stables R, Rodriguez A *et al.* Long-term safety and efficacy of percutaneous coronary intervention with stenting and coronary artery bypass surgery for multivessel coronary artery disease: a meta-analysis with 5-year patient-level data from the ARTS, ERACI-II, MASS-II, and SoS trials. *Circulation* 2008;118:1146–54.
- [16] Stettler C, Allemann S, Wandel S, Kastrati A, Morice MC, Schomig A *et al.* Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. *BMJ* 2008;337:a1331.
- [17] Daemen J, Kuck KH, Macaya C, LeGrand V, Vrolix M, Carrie D *et al.* ARTS II Investigators. Multivessel coronary revascularization in patients with and without diabetes mellitus: 3-year follow-up of the ARTS-II (Arterial Revascularization Therapies Study-Part II) trial. *J Am Coll Cardiol* 2008;52:1957–67.
- [18] Kapur A, Hall RJ, Malik IS, Qureshi AC, Butts J, de Belder M *et al.* Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. *J Am Coll Cardiol* 2010;55:432–40.
- [19] Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M *et al.* Strategies for multivessel revascularization in patients with diabetes. *N Engl J Med* 2012;367:2375–84.
- [20] Mohr FW, Rastan AJ, Serruys PW, Kappetein AP, Holmes DR, Pomar JL *et al.* Complex coronary anatomy in coronary artery bypass graft surgery: impact of complex coronary anatomy in modern bypass surgery? Lessons learned from the SYNTAX trial after two years. *J Thorac Cardiovasc Surg* 2011;141:130–40.
- [21] Head SJ, Mack MJ, Holmes DR Jr, Mohr FW, Morice MC, Serruys PW *et al.* Incidence, predictors and outcomes of incomplete revascularization after percutaneous coronary intervention and coronary artery bypass grafting: a subgroup analysis of 3-year SYNTAX data. *Eur J Cardiothorac Surg* 2012;41:535–41.
- [22] Farooq V, Vergouwe Y, Räber L, Vranckx P, Garcia-Garcia H, Diletti R *et al.* Combined anatomical and clinical factors for the long-term risk stratification of patients undergoing percutaneous coronary intervention: the Logistic Clinical SYNTAX score. *Eur Heart J* 2012;33:3098–104.
- [23] Park K, Park KW, Rha SW, Bae JH, Hur SH, Park JS *et al.* Comparison of 5-year clinical outcomes between sirolimus-versus paclitaxel-eluting stent: Korean multicenter network analysis of 9000-patient cohort. *Circ Cardiovasc Interv* 2012;5:174–84.
- [24] Stone GW, Kedhi E, Kereiakes DJ, Parise H, Fahy M, Serruys PW *et al.* Differential clinical responses to everolimus-eluting and Paclitaxel-eluting coronary stents in patients with and without diabetes mellitus. *Circulation* 2011;124:893–900.
- [25] National Cholesterol Education Program Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation* 2002;106:3143–421.

APPENDIX. CONFERENCE DISCUSSION

Dr D. Taggart (Oxford, UK): I received this paper for review in advance of the meeting, and my only comment is that in the abstract it says there were no differences in any of the primary end points, but in fact there is a 7% difference in mortality comparing diabetics and non-diabetics, and if you look at the insulin versus the non-insulin group, the difference in mortality is 10%. So my suggestion to the authors of the paper would be to list these in the abstract, because most people who go on MEDLINE read the abstract; they do not download the paper. So they will be given a false impression that there is no difference in mortality in these groups that may not have reached conventional statistical significance because the numbers are relatively small. But anything that gives you a mortality benefit of between 7 to 10% is clinically very important and that should be in the abstract.

One of the things I found counter-intuitive when I read this paper was that there was no difference in the SYNTAX score between the diabetic and the non-diabetic population. Now, I have always said and maintained, and we all believe that diabetics have more severe diffuse coronary artery disease, so I was going to ask, can you explain why, at least according to the SYNTAX score, there didn't seem to be any difference?

Dr Kappetein: We will highlight this, and you are absolutely right. I didn't have the time to show the difference between the insulin-treated ones and the non-insulin-treated diabetic patients, but there is a significant difference also in mortality between the two. As you could see, the *P*-value was 0.06, and you are right, we should not focus too much on this, whether it's 0.06 or 0.05. In two weeks' time we will have the results from the FREEDOM trial presented, which randomized CABG versus PCI in only diabetic patients: this study includes a much larger diabetic population, and hopefully we will see a significant difference there.

In patients with a low SYNTAX score, there was no difference between CABG and PCI. So you could say that those patients with diabetes that have a low SYNTAX score are probably a different type from those patients with a high SYNTAX score. Patients with a low SYNTAX score are patients with their glucose under control and therefore their disease is not as severe as the ones with not so very well controlled glucose treatment. In patients with a high SYNTAX score, findings are the same as in the overall cohort, and CABG is doing much better.

We can make the comparison with patients with peripheral vascular disease: there are diabetic patients who do very badly and need amputations, but there are also diabetic patients who do quite well and are well controlled.

Dr P. Sergeant (Leuven, Belgium): Can you repeat to us the definition of diabetes in the SYNTAX trial?

Dr Kappetein: The group of patients that I showed were the patients that were medically-treated and insulin-treated. We have also made a split between the medically-treated ones and the insulin-treated ones, and if you only look at the insulin-treated group, then there is a significant difference also in cardiac mortality, but not in the medically-treated diabetic patients.

Dr Sergeant: So in reality you should not have combined the orally-treated and the insulin-treated?

Dr Kappetein: You are absolutely right. In the manuscript we have split these two.